XTalks

FEBRUARY 8, 2021

Last year, Biocon Biologics and Mylan announced they’d be seeking interchangeable status for their long-acting insulin product Semglee , developed to be an alternative to Sanofi’s Lantus (insulin glargine).

Production 78

Production Insulin Branding Generic Drugs 78

XTalks

JUNE 5, 2023

GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness. Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the GLP-1 hormone released in the gastrointestinal tract after eating.

FDA Approval 98

FDA Approval Containment Drugs Pharmacy 98

XTalks

JANUARY 25, 2023

XTALKS WEBINAR: Review of Key Trends for Life Science Commercial Teams in 2023 Register for this free on-demand webinar to learn about the latest trends in sales and marketing campaigns that could help bolster commercial success for life science companies this year.

FDA Approval 52

FDA Approval Drugs Life Science Cosmetics 52

XTalks

JANUARY 5, 2024

Related: Zepbound, Obesity Version of Eli Lilly’s Mounjaro, Finally Gets FDA Nod So far, LillyDirect provides support for 14 Lilly medicines, with 12 being different formulations and types of insulin. In addition to these and Zepbound, Lilly’s medication for migraine management, Emgality (galcanezumab), is also available through the website.

Drugs 59

Drugs Pharmacy Cosmetics Medicine 59

XTalks

AUGUST 2, 2023

It is a dipeptidyl peptidase-4 inhibitor that keeps insulin levels stable and reduces the amount of glucose produced by the body. 2) Botox Therapeutic/Cosmetic Botox, or botulinum neurotoxin, is a neurotoxic protein produced by the Clostridium botulinum bacteria. Merck’s total global revenue from Lagevrio was $5.68 billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98